No treatment protocol of proven efficacy was approved to manage COVID-19 and we present a novel COVID-19 immunomodulatory protocol basing on our early pioneering article that justified repurposing nitazoxanide/azithromycin combination for early cases of COVID-19 which was followed by two articles to justify addition of non-steroidal anti-inflammatory drugs to nitazoxanide/azithromycin and recently an article that illustrates the potential immunomodulatory mechanisms by which all the drugs used might benefit COVID-19 patients has been published. We have managed more than 50 confirmed and highly suspected COVID-19 patients, mostly via telemedicine, while fully presenting a case series of 37 COVID-19 Arab patients including 12 confirmed by PCR and 23 diagnosed by other measures. The patients included 14 adult males including an immunocompromised patient, 16 adult females including one lactating, 3 pregnant patients including one confirmed by PCR as well as 4 children. All patients have received a short 5-day-regimen of NSAIDs (diclofenac potassium in most of cases, ibuprofen, lornoxicam, meloxicam, celecoxi